|Bid||14.44 x 900|
|Ask||14.78 x 800|
|Day's Range||13.73 - 14.76|
|52 Week Range||12.16 - 41.82|
|Beta (5Y Monthly)||-0.26|
|PE Ratio (TTM)||7.71|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MRVI
Three Motley Fool contributors were asked to identify great growth stocks down 20% or more to buy now. Here's why they chose Beam Therapeutics (NASDAQ: BEAM), Maravai LifeSciences (NASDAQ: MRVI), and Novavax (NASDAQ: NVAX). Keith Speights (Beam Therapeutics): Beam Therapeutics was flying high in the early part of 2021.
As any biotech investor will tell you freely, investing in biopharma is rife with risks. Clinical trials can miss the mark, and successful medicines on the market can get outcompeted by newer entrants. To do that, they tend to have a mix of reliable sales alongside a bunch of ambitious projects to provide upside.
In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20. The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a […]